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This discussion session was centered around three
basic topics: I. Factors which modulate graft rejection
including tolerance, II. Mechanisms of graft rejection,
and III. Structure of target antigens in the allograft
reaction. Α number of selected contributors were invited
to summarize and discuss their data in view of these topics.
The first topic was addressed by Eis Goulmy who on
behalf of Jon van Rood presented evidence for neonatal Β
cell tolerance in man. Studies in highly sensitized
patients waiting for renal allografting with broadly reac-
tive anti-HLA antibodies in their sera revealed that in 50%
of the patients antibodies were not formed against the non
inherited maternal antigens (MIKAs). These findings may
have inportant implications not only for renal allograft
selection but mght also add significant Information for
selection between potential unrelated bone marrow donors.
Whether the tolerance is due to chimerisn is not known: yet
if so, it only would partially explain the data. Α human
model dealing with acquired tolerance or factors which
modulate "graft rejection was presented by Malies Lagaaij
(Leiden). Her data indicated that not all blood transfu-
sions given prior to kidney transplantation resulted in
better graft survival. Depencing on sharing of HLA-DR or
not between patient and transfusion donor determines
whether the transfusion innunosuppresses or imnunizes,
respectively. In the latter Situation; i.e., HLA-DR
Eismatched transfusions, cellular KLC and CKL in vitro
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activities as well as humoral responses xncrease and graft
survival decreases. Whether class I matching between reci-
pient and transfusion donor is playing a role is not clear,
although the best results for graft survival are obtained
in those cases where the sharing of HLA class I and II be-
tween recipient, blood transfusion donor and kidney donor
is the greatest. The mechanism is unknown but might be a
veto cell type of phenomenon. Next, an interesting animal
model focusing on the induction of tolerance for seif anti-
gens was presented by Brigitta Stockinger (Basel). The
seif protein C5 is processed and presented with class II
from normal mice and can activate C5 specific Τ cell clones
obtained from C5 deficient mice. The C5 deficient mice are
not tolerant to this protein as expected, but they are also
not tolerant to the C5 precursor molecule pro-C5. Further-
more, Τ cell clones from deficient mice react with pro-C5
from C5 deficient macrophages. This lack of tolerance to
pro-C5 may be due to either expression of low levels of
this seif antigen or low levels of class II molecules on
cells responsible for tolerance induction in the thymus. Α
model for explaining tolerance to skin grafts was presented
by Michael Rees (NIH). Mice grafted with Qa-1 congenic skin
grafts do not reject this tissue unless the graft expresses
a second helper antigen. Mice first grafted with Qa-1 dis-
parate grafts lacking the helper antigen fail to reject
this graft when re-grafted with a Qa-1 graft bearing the
helper antigen. Adoptive transfer of spieen cells from Qa-1
tolerant mice together with anti-Qa-1 primed effector cells
suppressed the abllity of the effector cells to mediate
graft rejection. The phenotype of these suppressor cells
has not yet been established. Ken Murphy (St. Louis) pro-
duced transgenic mice which expressed IA on exocrine pan-
creatic cells. The IA on the pancreatic cells was shown to
be capable of presenting peptide antigen to specific IA
restricted hybridomas. These same cells when cultured with
Τ cell clones were able to inactivate these Τ cells. Trans-
fer of normal cells into these recipients resulted in tissue
destruction of the exocrine pancreas. This model suggests
peripheral tolerance of Τ cells potentially reactive
against organ specific antigens not expressed in the thymus.
The second part of the Session addressed the mechanism
of graft rejection. Amy Rosenberg (NIH) focused on skin
allografts, the effector cell populations involved in rejec-
tion of MHC class I or II disparate grafts, and the neces-
sity of IA expression on the target cell for rejection of
class II disparate grafts. The specificity of rejection
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was addressed using cUimeras and allophenic mice. The
results indicated that rejection was directed against cells
bearing the target antigen and that bystander effects did
not cause destruction to other cells in the graft. Hugh
Auchincloss (Boston) showed in a xenogeneic model using
monkey skin on mice that CD4 + and CD8 + cells were re-
sponsible for graft rejection. He also reported only a
weak allogeneic Τ cell response mediated by mouse Τ cells
against monkey stimulator cells unless mouse antigen pre-
senting cells were present in in vitro cultures. His data
suggests that for xenografts rhat target antigens only need
be expressed on class II positive epidermal cells.
The third section addressed the structure of target
antigens and how they may affect graft rejection. Jim
Forman analyzed Τ cell recognition of an hybrid class I
molecule (Ld/Q7) having H-2Ldol-l aad Λ-2 domains with the
Λ -3 domain and carboxy-end derived from Q7 (Qa-2). Surpri-
singly, anti-H-2Ld bulk and cloned CTL failed to recognize
this antigen. However, secondary CTL from in vivo primed
animals could recognize this molecule. These latter CTL
were not inhibited from mediating lysis by anti-Lyt-2 anti-
bodies, whereas primary CTL were. This suggests that this
hybrid molecule lacks the abiüity to interact with Lyt-2
and could explain why Qa-2 molecules do not act as restric-
tion elements for antigen specific CTL. This data would
further indicate a major role for the function of Lyt-2 for
antigen specific CTL responses. Andrew Mellor (London)
used Q9 (Qa~2) H-2D hybrid genes to produce transgenic
mice. The mice expressed Q9/D or Q9 at relatively high
levels on many tissues. The Q9 molecule was linked to the
cell membrane through phosphatidylinositol while the Q9/D°
was not. Both served as transplantation antigens and were
capable of inducing CTL activity against Qa-2 antigens.
Edward Barksdale (Boston) examined the expression of class
I and II transcripts and antigens in fetal tissue trans-
planted into allogeneic recipients. There was an inverse
correlation between MHC expression and graft survival. He
also reported that epidermal growth factor inhibited MHC
mRNA while Mullerian inhibiting substance had an opposite
effect. Thus, substances involved in the growth and dif-
ferentiation of embryonic and fetal tissue appears to also
regulate the expression of MHC transcription.
